Stabilis stands at the forefront of NMES (Neuromuscular Electrical Stimulation) technology, revolutionizing the landscape of wellness improvement for mild to moderate Parkinson's patients. Pioneering the fusion of cutting-edge stimulation wearables and technology, Stabilis's electro-muscle activation devices offer tailored nerve-targeting and muscle strengthening to its patients. Those with mild to moderate Parkinson's, who struggle with the disease on a daily basis serve as the initial target for Stabilis's wearable therapy. The company is currently in medical trials, boasts the support of prominent investors in the healthcare and technology industries, and is eager to continue the journey of improving quality of life for Parkinson's patients.